TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02765659

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mzake ndi Mzake T1
Description: a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mzake ndi Mzake T2
Description: a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mzake ndi Mzake T3
Description: a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
Study: NCT03314285

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Quality
Description: Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Quality
Description: Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
Study: NCT04049825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: OPB-111077+bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: OPB-111077+rituximab+bendamustine
Study: NCT03254056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Berci technique
Description: Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
Study: NCT00527202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: Botulinum toxin A versus saline in parallel groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin A
Description: Botulinum toxin A versus saline in parallel groups
Study: NCT04599426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cell regimen group
Description: 10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 .
Study: NCT03500744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ropivacaine 0.5% 20 mL at each site of ESPB

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block
Description: Skin infiltration only
Study: NCT00864734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
Description: A: Experimental Subjects received Alpharma formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study: NCT03787069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv Lignocaine vs placebo
Description: Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iv Lignocaine vs placebo
Description: Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
Study: NCT03584009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
Study: NCT00260221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: using VR hypnosis/distraction and audio hypnosis
Description: a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: using VR hypnosis/distraction and audio hypnosis
Description: a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: using VR hypnosis/distraction and audio hypnosis
Description: a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
Study: NCT03759158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet twice daily.
Study: NCT02224430

Intervention type: DEVICE
Intervention: schizophrenia/schizoaffective disorder.
Description: Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
Study: NCT04210479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Filled-bladder
Description: Urinary bladder filling with 300 ml diluted methylene blue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non filled-bladder
Description: Pull up the empty (non-filled) urinary bladder using Allis forceps
Study: NCT02886715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.1%
Description: Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac®
Description: Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
Study: NCT01129947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA 25 mg tid
Study: NCT05387486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Landmark technique
Description: anatomical landmarks (sternocleidomastoid muscles, sternal notch, cricoid cartilage, carotid artery and clavicle) will be palpated. A 3cc syringe with 21 gauge needle (locator) will be used first to locate IJV at the apex of the triangle formed by the two heads of the sternocleidomastoid muscle. After successful location, an introducer needle of 18 gauge, attached with a 5 ml syringe, will be inserted at the same point. The introducer needle will be directed towards the ipsilateral nipple at an angle of 20-30° with the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided pre location technique
Description: In Group Ultrasound-guided pre location technique, venipuncture site will be determined using ultrasound probe which will be then removed and locator needle of 21 gauge will be used first to confirm IJV location. The cannulation or venipuncture will be performed at the marked point of locator needle by the use of 18 gauge introducer needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided real-time technique
Description: In Group Ultrasound-guided real-time technique, cannulation or venipuncture will be performed under real-time imaging using 18 gauge needle i-e ultrasound will be used for prelocation and puncturing of IJV and locator needle will not be used
Study: NCT02535559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens Against Tobacco Use
Description: Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
Study: NCT02169219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered in four weekly doses at 375mg/m2
Study: NCT00881010

Intervention type: BEHAVIORAL
Intervention: Telephone Intervention
Description: Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
Study: NCT03304444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine hydrochloride used in TAP block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: liposomal bupivacaine used in TAP block
Study: NCT01351870

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fractionation Regimen
Description: 1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated Radiotherapy
Description: 1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy
Study: NCT03505931

Intervention type: DEVICE
Intervention: Implantation of Eluvia stent
Description: Implantation of Eluvia stent
Study: NCT02102373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350
Description: Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350
Description: Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
Study: NCT01644370

Intervention type: DRUG
Group type: OTHER
Intervention: HAART
Description: as per Thai HIV Treatment guidelines

Intervention type: DRUG
Group type: OTHER
Intervention: HAART
Description: as per Thai HIV Treatment guidelines
Study: NCT00881010

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
Study: NCT03816592

Intervention type: PROCEDURE
Intervention: Opioid free anaesthesia
Description: patient anesthtesized with lidocaine, ketamine and dexamethasone

Intervention type: PROCEDURE
Intervention: Opioid anaesthesia
Description: patients anesthetized with sufentanil ketamine and dexamethasone
Study: NCT00825773

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty
Description: Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty
Description: Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
Study: NCT00579085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Ketamine .35mg/kg times ten days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV NSS
Description: Placebo inactive ingredients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)
Study: NCT01077752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous ropivacaine preperitoneal infusion
Description: Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous lidocaine infusion
Description: Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parenteral analgesia combining acetaminophen and morphine
Description: parenteral analgesia combining acetaminophen and morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parenteral analgesia combining acetaminophen and morphine
Description: parenteral analgesia combining acetaminophen and morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: parenteral analgesia combining acetaminophen and morphine
Description: parenteral analgesia combining acetaminophen and morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl
Study: NCT04113811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)
Description: In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
Study: NCT02686190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luxtherapy
Study: NCT02115126

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMP2A-loaded conventional DC vaccine
Description: Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be \> 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be \> 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DUK-CPG-001
Description: On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination.
Study: NCT01830777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Intravenously on Days 3-7 of re-induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Intravenously on Days 3-7 of re-induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenously on Days 3-7 of re-induction therapy.
Study: NCT04241679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Nerve Test System
Description: The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery.
Study: NCT03486275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygie
Description: Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Source articles
Description: 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
Study: NCT01063777

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 12 week exercise therapy program and patient education.
Description: The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
Study: NCT01705782

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: E. coli endotoxin, US standard

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. coli endotoxin, US standard
Study: NCT04334018

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional CRT
Description: Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPP CRT
Description: CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
Study: NCT02695212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral
Study: NCT03444077

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.
Description: The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STTTOPPP the bleeding
Description: * Surgical team pre-activation~* Trauma team pre-activation~* Transfusion team pre-activation~* Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~* O negative RBC transfusion as soon as possible~* Plasma and Platelets transfusion as soon as possible~* Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~* Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Care
Description: Regular local pre-hospital care.
Study: NCT02290431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 (panobinostat)
Description: Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
Study: NCT04111419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET
Description: amlodipine/atorvastatin (5/20mg tablet) once a day
Study: NCT02290431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)